estherpoon / Shutterstock.com
As the ‘UK+’ exhaustion regime is set to continue for now, Rebecca Anderson-Smith of Mewburn Ellis explores how pharma firms should protect their rights.
Ever since the UK announced its intended departure from the European Union (EU), there has been much speculation about whether and how the UK would amend its trademark exhaustion and parallel trade regime. Following the recent UK government consultation, the position has become clearer, although the government has not ruled out the possibility of making further changes in the future.
What do we mean by exhaustion and parallel trade?
The doctrine of exhaustion of IP rights is a principle that limits an IP owner’s power to enforce their rights once the goods have been placed on the market by the IP owner or with their consent. Parallel trade is the import and export of genuine goods which have already been put on the market and in which the IP owner’s rights are exhausted. Together, laws on exhaustion and parallel trade help to strike a balance between the limited monopoly created by IP rights and the need to encourage competition in the market.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Parallel trade, trademarks, Mewburn Ellis, pharma firms, EEA, IP rights, CITMA, CIPA